^
    Back
    Association details:
    Biomarker:BRAF-ZC3H7A fusion
    Cancer:Lung Adenocarcinoma
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Research Square
    Title:

    Case report: BRAF-MAD1L1 and BRAF-ZC3H7A: novel gene fusion in Rhabdomyosarcoma and Lung adenocarcinoma

    Excerpt:
    First-generation sequencing (Sanger) conrmed the BRAF-ZC3H7A gene fusion in the LADC patient (Figure.5). In March 2017, CT scans showed rapid disease progression and the patient died with failing to use sorafenib, which was recommended as the second-line therapy.
    DOI:
    10.21203/rs.3.rs-58002/v1